Supplemental material
Journal of Medical Economics
Volume 26, 2023 - Issue 1
Oncology
Cost-effectiveness of apixaban and rivaroxaban in thromboprophylaxis of cancer patients treated with chemotherapy in Spain
Andrés J. Muñoza Medical Oncology Service, Instituto de Investigación Sanitaria Gregorio Marañón, Universidad Complutense, Madrid, SpainCorrespondence[email protected]
https://orcid.org/0000-0001-6977-8249
https://orcid.org/0000-0001-6977-8249, Laura Ortegaa Medical Oncology Service, Instituto de Investigación Sanitaria Gregorio Marañón, Universidad Complutense, Madrid, Spainhttps://orcid.org/0000-0003-0456-7322
https://orcid.org/0000-0003-0456-7322, Ana Gutiérreza Medical Oncology Service, Instituto de Investigación Sanitaria Gregorio Marañón, Universidad Complutense, Madrid, Spainhttps://orcid.org/0000-0002-6080-0195
https://orcid.org/0000-0002-6080-0195, Enrique Gallardob Medical Oncology Service, Parc Taulí Hospital Universitari, Institut d’Investigació i Innovació Parc Taulí I3PT, Universitat Autònoma de Barcelona. Sabadell, Spainhttps://orcid.org/0000-0002-1375-3488
https://orcid.org/0000-0002-1375-3488, , , Blanca Moróna Medical Oncology Service, Instituto de Investigación Sanitaria Gregorio Marañón, Universidad Complutense, Madrid, Spainhttps://orcid.org/0000-0001-7000-4734
https://orcid.org/0000-0001-7000-4734, Pilar García-Alfonsoa Medical Oncology Service, Instituto de Investigación Sanitaria Gregorio Marañón, Universidad Complutense, Madrid, Spainhttps://orcid.org/0000-0002-4373-9978
https://orcid.org/0000-0002-4373-9978 & José Manuel Soriad Institut de Recerca, Hospital de la Santa Creu i Sant Pau, Barcelona, Españahttps://orcid.org/0000-0002-6226-4293
https://orcid.org/0000-0002-6226-4293 show all